<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725059</url>
  </required_header>
  <id_info>
    <org_study_id>3475-756</org_study_id>
    <secondary_id>2017-004869-27</secondary_id>
    <secondary_id>MK-3475-756</secondary_id>
    <secondary_id>194604</secondary_id>
    <secondary_id>KEYNOTE-756</secondary_id>
    <nct_id>NCT03725059</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy &amp; Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)</brief_title>
  <official_title>A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475)
      versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant
      (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage
      estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-)
      breast cancer.

      The primary study hypotheses are: 1) pembrolizumab is superior to placebo, both in
      combination with the protocol-specified neoadjuvant anticancer therapy, as assessed by
      pathological Complete Response (pCR) rate defined by the local pathologist, and 2)
      pembrolizumab is superior to placebo (both in combination with the protocol-specified
      neoadjuvant and adjuvant anticancer therapies) as assessed by Event-Free Survival (EFS) as
      determined by the investigator. The study is considered to have met its primary objective if
      pembrolizumab is superior to placebo with respect to either pCR (ypT0/Tis ypN0) or EFS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will receive 8 cycles of neoadjuvant study treatment and then will undergo
      surgery for their breast cancer. After surgery, participants will receive 9 cycles of study
      treatment and up to 10 years of variable endocrine therapy. Each cycle is 21 days long.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2018</start_date>
  <completion_date type="Anticipated">January 24, 2031</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2031</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0</measure>
    <time_frame>Up to approximately 7 months (Time of surgery)</time_frame>
    <description>The pCR rate (ypT0/Tis ypN0) is defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by American Joint Committee on Cancer (AJCC) staging criteria (7th edition) assessed by the local pathologist at the time of definitive surgery. The percentage of participants with a pathological Complete Response (pCR) using the definition of (ypT0/Tis ypN0) will be presented for pembrolizumab versus placebo, both in combination with the protocol-specified neoadjuvant anticancer therapies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>EFS is defined as the time from randomization to disease progression that: precludes definitive surgery, results in a local or distant recurrence, results in a second primary malignancy, or death due to any cause whichever occurs first. The EFS following administration of pembrolizumab and placebo, both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies, as determined by the investigator will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>OS is defined as the time from date of randomization to date of death due to any cause. The OS following administration of pembrolizumab and placebo, both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR Rate Using the Definition of ypT0ypN0</measure>
    <time_frame>Up to approximately 7 months (Time of surgery)</time_frame>
    <description>pCR rate (ypT0ypN0) is defined as the percentage of participants without residual invasive or in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy by AJCC staging criteria (7th edition) assessed by the local pathologist at the time of definitive surgery. The percentage of participants with a pCR using the definition of (ypT0ypN0) will be presented for pembrolizumab versus placebo, both in combination with the protocol-specified neoadjuvant anticancer therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR Rate Using the Definition of ypT0/Tis</measure>
    <time_frame>Up to approximately 7 months (Time of surgery)</time_frame>
    <description>pCR rate (ypT0/Tis) is defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen (independent of lymph node involvement) after completion of neoadjuvant systemic therapy by AJCC staging criteria (7th edition) assessed by the local pathologist at the time of definitive surgery. The percentage of participants with a pCR using the definition of ypT0/Tis will be presented for pembrolizumab versus placebo, both in combination with the protocol-specified neoadjuvant anticancer therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR Rate Using the Definitions of ypT0/Tis ypN0, ypT0/Tis, and ypT0 ypN0 in Participants With a Combined Positive Score [CPS] ≥1</measure>
    <time_frame>Up to approximately 7 months (Time of surgery)</time_frame>
    <description>pCR rates were calculated using the definitions of ypT0/Tis ypN0, ypT0/Tis, and ypT0 ypN0 after completion of neoadjuvant systemic therapy by AJCC staging criteria (7th edition) assessed by the local pathologist at the time of definitive surgery. The percentage of participants with a pCR using the three definitions of ypT0/Tis ypN0, ypT0/Tis, and ypT0 ypN0 in participants with a CPS ≥1 (with a positive Programmed Cell Death-Ligand 1 [PD-L1] tumor status) will be presented for pembrolizumab versus placebo, both in combination with the protocol-specified neoadjuvant anticancer therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS in Participants With a CPS ≥1</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>EFS is defined as the time from randomization to disease progression that: precludes definitive surgery, results in a local or distant recurrence, results in a second primary malignancy, or death due to any cause whichever occurs first. The EFS following administration of pembrolizumab and placebo, both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies, as determined by the investigator for participants with a CPS ≥1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in Participants With a CPS ≥1</measure>
    <time_frame>Up to approximately 12 years</time_frame>
    <description>OS is defined as the time from date of randomization to date of death due to any cause. The OS following administration of pembrolizumab and placebo, both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies for participants with a CPS ≥1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 15 months</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE while receiving pembrolizumab or placebo (including 1 month of safety follow up) will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing a Serious Adverse Event (SAE)</measure>
    <time_frame>Up to approximately 17 months</time_frame>
    <description>An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity or Is a congenital anomaly/birth defect. The number of participants who experience an SAE while receiving pembrolizumab or placebo (including 3 months of safety follow up) will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Immune-related AE (irAE)</measure>
    <time_frame>Up to approximately 15 months</time_frame>
    <description>Some AEs that may occur in this study that are known to be related to pembrolizumab immunotherapy treatment and may include: pneumonitis, diarrhea/colitis, aspartate aminotransferase/alanine aminotransferase (AST/ALT) elevation or increased bilirubin, Type 1 diabetes mellitus or hyperglycemia, hypophysitis, hyperthyroidism, hypothyroidism, nephritis and renal dysfunction, and myocarditis. The number of participants who experience an irAE while receiving pembrolizumab or placebo (including 1 month of safety follow up) will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Study Treatment Discontinuations Due to AEs</measure>
    <time_frame>Up to approximately 14 months</time_frame>
    <description>The number of participants who discontinue study treatment (pembrolizumab or placebo) due to an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire Core 30 (QLQ-C30) Score</measure>
    <time_frame>Baseline (Cycle 1 Day 1 in Treatment 1) and Cycles 1 and 4 Day 1 in Treatment 2 (Up to approximately 5 months) Each cycle is 21 days.</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Individual responses for each of 28 items are given on a 4-point scale (1=Not at All to 4=Very Much), with a lower score indicating a better outcome, and responses for each of 2 items (overall health and overall quality of life) are given on a 7-point scale (1=Very poor to 7=Excellent), with a higher score indicating a better outcome. The change from Baseline to end of treatment (up to Cycle 4 Day 1) in EORTC-QLQ-C30 scores for participants will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC Breast Cancer-Specific QoL Questionnaire (QLQ-BR23) Score</measure>
    <time_frame>Baseline (Cycle 1 Day 1 in Treatment 1) and Cycles 1 and 4 Day 1 in Treatment 2 (Up to approximately 5 months) Each cycle is 21 days.</time_frame>
    <description>The EORTC QLQ-BR23 is a 23-item questionnaire developed to assess the quality of life in women with breast cancer. Responses for each item are given on a 4-point scale (1=Not at All to 4=Very Much), with a lower score indicating a better outcome. The change from Baseline to end of treatment (up to Cycle 4 Day 1) in EORTC QLQ-BR23 score for participants will be presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1140</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the neoadjuvant setting, participants receive pembrolizumab (K) 200 mg via intravenous (IV) infusion once every 3 weeks (Q3W) + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by pembrolizumab 200 mg via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion Q3W for 4 cycles (Treatment 2). At 3 to 6 weeks after last cycle of neoadjuvant treatment, participants will undergo definitive surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive pembrolizumab 200 mg via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Chemotherapy (PX/PA[E]C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the neoadjuvant setting, participants receive placebo (P; normal saline or dextrose) via IV infusion Q3W + paclitaxel (X) 80 mg/m^2 via IV infusion once weekly (QW) for 4 cycles (Treatment 1), followed by placebo via IV infusion + doxorubicin or epirubicin (A or E; 60 mg/m^2 or 100 mg/m^2) via IV infusion Q3W + cyclophosphamide (C) 600 mg/m^2 via IV infusion Q3W for 4 cycles (Treatment 2). At 3 to 6 weeks after last cycle of neoadjuvant treatment, participants will undergo definitive surgery for their breast cancer. After surgery, participants will begin adjuvant study treatment. In the adjuvant setting, participants receive placebo via IV infusion Q3W for 9 cycles + variable endocrine therapy for up to 10 years. Each cycle is 21 days long.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab (K)</intervention_name>
    <description>IV infusion Q3W</description>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (P)</intervention_name>
    <description>Normal saline or dextrose IV infusion Q3W</description>
    <arm_group_label>Placebo+Chemotherapy (PX/PA[E]C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel (X)</intervention_name>
    <description>IV infusion QW</description>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy (PX/PA[E]C)</arm_group_label>
    <other_name>TAXOL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin (A)</intervention_name>
    <description>IV infusion Q3W</description>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy (PX/PA[E]C)</arm_group_label>
    <other_name>ADRIAMYCIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin (E)</intervention_name>
    <description>IV infusion Q3W</description>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy (PX/PA[E]C)</arm_group_label>
    <other_name>ELLENCE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (C)</intervention_name>
    <description>IV infusion Q3W</description>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy (PX/PA[E]C)</arm_group_label>
    <other_name>CYTOXAN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>Variable endocrine therapy for up 10 years</description>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Variable radiation therapy per local standard of care</description>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy (PX/PA[E]C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Definitive surgery for breast cancer</description>
    <arm_group_label>Pembrolizumab+Chemotherapy (KX/KA[E]C)</arm_group_label>
    <arm_group_label>Placebo+Chemotherapy (PX/PA[E]C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a localized invasive breast ductal adenocarcinoma, confirmed by the local
             pathologist, that includes either T1c-T2 (tumor size ≥2 cm), clinical node stage
             (cN)1-cN2, or T3-T4, cN0-cN2. Note: Inflammatory breast cancer is allowed.

          -  Has centrally confirmed ER+/HER2-, Grade 3 breast cancer of ductal histology,
             according to the most recent American Society of Clinical Oncology/College of American
             Pathologist guidelines.

          -  Provides a new or recently obtained core needle biopsy, consisting of multiple cores,
             taken from the primary breast tumor(s) for central determination of HR status (ER and
             progesterone receptor), HER2, grade, and PD-L1 status.

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as
             assessed within 10 days prior to initiation of study treatment.

          -  Male participants must agree to use contraception during the treatment period and for
             at least 12 months (for participants who received cyclophosphamide) or 6 months (for
             participants who did not receive cyclophosphamide) after the last dose of study
             treatment and refrain from donating sperm during this period.

          -  Female participants must agree to use effective contraception during the treatment
             period and for at least 12 months (for participants who received cyclophosphamide) or
             6 months (for participants who did not receive cyclophosphamide) after the last dose
             of study treatment with pembrolizumab or placebo.

          -  Has adequate organ function.

        Exclusion Criteria:

          -  Has a history of non-infectious pneumonitis that required treatment with steroids or
             has current pneumonitis.

          -  Has breast cancer with lobular histology.

          -  Has bilateral invasive breast cancer.

          -  Has metastatic (Stage IV) breast cancer.

          -  Has multi-centric breast cancer (presence of more than 1 tumor in different quadrants
             of the breast).

          -  Has any of the following clinical lymph node staging per current American Joint
             Committee on Cancer (AJCC) staging criteria for breast cancer staging based on
             radiological and/or clinical assessment: cN3, cN3a, cN3b, or cN3c.

          -  Has ER-, progesterone receptor positive breast cancer.

          -  Has undergone excisional biopsy of the primary tumor and/or axillary lymph nodes or
             has undergone sentinel lymph node biopsy prior to study treatment.

          -  Has a known additional, invasive, malignancy that is progressing or required active
             treatment in the last 5 years.

        Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the
        skin, ductal breast carcinoma in situ, or cervical carcinoma in situ that has undergone
        potentially curative therapy are not excluded.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study treatment.

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years (i.e., with use of disease modifying agents, corticosteroids, or
             immunosuppressive drugs) Note: Replacement therapy (e.g. thyroxine, insulin, or
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)
             is not considered a form of systemic treatment.

          -  Has a known history of active tuberculosis (Bacillus tuberculosis).

          -  Has an active infection requiring systemic therapy.

          -  Has left ventricular ejection fraction (LVEF) of &lt;50% or below the institution limit
             of normal, as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
             performed at screening.

          -  Has other significant cardiac disease, such as: 1) History of myocardial infarction,
             acute coronary syndrome, or coronary angioplasty/stenting/bypass within the last 6
             months; or 2) Congestive heart failure (CHF) New York Heart Association (NYHA) Class
             II-IV or history of CHF NYHA Class III or IV.

          -  Has a known history of human immunodeficiency virus (HIV) infection.

          -  Has a known history of hepatitis B or known active hepatitis C virus infection.

          -  Has received prior treatment for breast cancer.

          -  Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1),
             anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent
             directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic
             T-lymphocyte-associated protein 4 [CTLA-4], OX 40, CD137).

          -  Has received a live vaccine within 30 days prior to the first dose of study treatment.

          -  Has severe hypersensitivity (≥Grade 3) to any of the components or excipients used in
             the study treatments.

          -  Is/was enrolled in a study of an investigational agent and received study therapy, or
             used an investigational device within 4 weeks (12 months for an investigational agent
             or device with anticancer or antiproliferative properties) prior to the first dose of
             study treatment.

          -  Is pregnant, breastfeeding, or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 12 months
             (for participants who received cyclophosphamide) or 6 months (for participants who did
             not receive cyclophosphamide) after the last dose of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Cancer Center, PC ( Site 8003)</name>
      <address>
        <city>Daphne</city>
        <state>Alabama</state>
        <zip>36526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Western Regional Medical Center ( Site 0001)</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>623-207-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates PC- HOPE ( Site 8008)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0079)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-967-4335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital Cancer Center ( Site 0004)</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-962-4562</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center ( Site 0072)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-723-0658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center ( Site 0073)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>916-703-5560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center ( Site 0008)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-9351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Baptist ( Site 0014)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>904-202-7468</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Regional Medical Center, Inc. ( Site 0075)</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>770-400-6633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orchard Healthcare Research Inc. ( Site 0020)</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>224-534-7580</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Medical Center, Inc. ( Site 0077)</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>847-731-1777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Goshen Center for Cancer Care ( Site 0021)</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>574-364-2888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MercyOne Waterloo Cancer Center ( Site 0016)</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center ( Site 0022)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-562-4370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A. ( Site 8007)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ( Site 0024)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-643-2208</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MGH - North Shore Cancer Center ( Site 0081)</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <zip>01923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>978-882-6047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MGH Newton-Wellesley Hospital's Vernon Cancer Center ( Site 0082)</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-831-7505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System ( Site 0028)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-2438</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic and Medical School (Rochester) ( Site 0029)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>507-538-1115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center ( Site 0033)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-238-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists ( Site 0039)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-691-6971</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center ( Site 0041)</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>201-541-6312</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College ( Site 0043)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-362-9888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTCA Southwestern ( Site 0074)</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. ( Site 8000)</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center ( Site 0052)</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>877-204-6081</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center ( Site 0078)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-728-2792</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0076)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-537-7748</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina ( Site 0053)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-792-5853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC/The Sarah Cannon Research Institute ( Site 7000)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>844-482-4812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Central ( Site 8004)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Dallas Presbyterian Hospital ( Site 8002)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8009)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas-MD Anderson Cancer Center ( Site 0083)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-792-2817</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Plano East ( Site 8010)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler ( Site 8006)</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Francis Medical Center Oncology Research ( Site 0064)</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-893-8611</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates ( Site 8001)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-6507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology ( Site 0070)</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5097834637228</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates (Summit Cancer Centers) ( Site 0066)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-462-2273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris OBrien Lifehouse ( Site 2107)</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61295156183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital ( Site 2100)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61294631173</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital ( Site 2101)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298455200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Ltd ( Site 2106)</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731637689</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital ( Site 2103)</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61385595935</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre ( Site 2102)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61385595935</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis Bonheiden ( Site 0703)</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerpen</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3215504625</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet ( Site 0710)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3225417232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc ( Site 0701)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3227645435</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHC MontLegia ( Site 0707)</name>
      <address>
        <city>Liège</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3242248992</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis Campus Virga Jesse ( Site 0704)</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3211337960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Site de Godinne ( Site 0706)</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3281423858</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent ( Site 0700)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3292468462</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven ( Site 0702)</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3216346903</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge ( Site 0705)</name>
      <address>
        <city>Kortrijk</city>
        <state>West-Vlaanderen</state>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 0205)</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74605-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+556232437260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Ijui ( Site 0206)</name>
      <address>
        <city>Ijui</city>
        <state>Rio Grande Do Sul</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555533319393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associacao Hospitalar Moinhos de Vento ( Site 0201)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555133142839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0202)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555133203039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEPON - Centro de Pesquisas Oncologicas ( Site 0208)</name>
      <address>
        <city>Florianopolis</city>
        <state>Santa Catarina</state>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5548991252255</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0207)</name>
      <address>
        <city>Itajai</city>
        <state>Santa Catarina</state>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+554733485093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer - INCA HC III ( Site 0200)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+552132073810</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0209)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551138932528</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 0204)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01317-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5511991931500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0210)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551134744249</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute ( Site 0115)</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>7805778072</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Cancer-Vancouver Center ( Site 0116)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6046758000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0112)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>41694645012245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CISSS de la Monteregie-Centre ( Site 0108)</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>45046650003226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0111)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5142523400ext5853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0114)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514890800014186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital ( Site 0103)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514340822224210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Trois-Rivieres ( Site 0106)</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8196973333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0101)</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4186827511882422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences ( Site 3208)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>861087787679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital ( Site 3207)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>86059183357896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ( Site 3213)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510289</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8618922182851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital Of Hebei Medical University ( Site 3216)</name>
      <address>
        <city>Shijia Zhuang</city>
        <state>Hebei</state>
        <zip>050019</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8601031166696234</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital ( Site 3200)</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613904637161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital ( Site 3212)</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8617729798130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital ( Site 3211)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8618602726300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital ( Site 3214)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613973135318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University ( Site 3201)</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86431875661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hosp,Shanghai Jiao Tong University School of Medicine ( Site 3215)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862164370045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center ( Site 3205)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8602164175590</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital ( Site 3209)</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862223340123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University ( Site 3203)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8687236114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital.... ( Site 3210)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8605788122222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rodrigo Botero SAS ( Site 0407)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050030</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5743490791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0405)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+57444800162404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0400)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573369940209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica S.A. ( Site 0401)</name>
      <address>
        <city>Monteria</city>
        <state>Cordoba</state>
        <zip>230002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+57478543441302</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica del Country ( Site 0402)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5715300470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Universitaria Sanitas ( Site 0403)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5715956161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco de Cali S.A ( Site 0406)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+572682100014091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc ( Site 0920)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33380737504</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud IUCT Oncopole ( Site 0903)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Centre Rene Huguenin ( Site 0917)</name>
      <address>
        <city>Saint-Cloud</city>
        <state>Hauts-de-Seine</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33144324675</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Cancerologie du Grand Montpellier ( Site 0925)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467926155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR-METZ-THIONVILLE - Hopital de Mercy ( Site 0919)</name>
      <address>
        <city>Metz</city>
        <state>Moselle</state>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33387345128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret ( Site 0911)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320295935</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine ( Site 0916)</name>
      <address>
        <city>Avignon</city>
        <state>Provence-Alpes-Cote-d'Azur</state>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33490276397</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin ( Site 0909)</name>
      <address>
        <city>Clermont Ferrand Cedex</city>
        <state>Puy-de-Dome</state>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33473278137</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo ( Site 0906)</name>
      <address>
        <city>Le Mans</city>
        <state>Sarthe</state>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33243297908</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy ( Site 0926)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142114293</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie ( Site 0900)</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33144324686</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis ( Site 0908)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142494262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon ( Site 0914)</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33156016024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Management GmbH ( Site 1012)</name>
      <address>
        <city>Friedrichshafen</city>
        <state>Baden-Wurttemberg</state>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4975412899560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen ( Site 1001)</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4991318543463</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern ( Site 1000)</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4989440054317</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sana Klinikum Offenbach GmbH ( Site 1002)</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496984053850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 1004)</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49611432377</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynaekologisch-onkologische Praxis Hannover ( Site 1013)</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+495116555280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynaekologisches Zentrum ( Site 1003)</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4922890927661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte Gmbh Evang. Huyssens Stiftung ( Site 1006)</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4920117433005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritas Klinikum Saarbruecken St. Theresia ( Site 1009)</name>
      <address>
        <city>Saarbruecken</city>
        <state>Saarland</state>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496814061301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus ( Site 1008)</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493514586728</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Nordhausen gGmbH - Praxis Dr. Grafe ( Site 1005)</name>
      <address>
        <city>Nordhausen</city>
        <state>Thuringen</state>
        <zip>99734</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493631411626</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz ( Site 2913)</name>
      <address>
        <city>Kecskemet</city>
        <state>Bacs-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3676516719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 2905)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302457110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 2904)</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302780644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szent Margit Korhaz ( Site 2901)</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302507979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet ( Site 2908)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612248600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz ( Site 2902)</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209674709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 2907)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652255585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 2915)</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36304111268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital ( Site 1554)</name>
      <address>
        <city>Cork</city>
        <zip>T12 DV56</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+353214542807</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. James s Hospital ( Site 1553)</name>
      <address>
        <city>Dublin</city>
        <zip>D08 K0Y5</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+353014103000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assuta Ashdod Public ( Site 1704)</name>
      <address>
        <city>Ashdod</city>
        <state>HaDarom</state>
        <zip>7747629</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236973816</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 1701)</name>
      <address>
        <city>Beer Sheva</city>
        <state>HaDarom</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97286244127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center ( Site 1710)</name>
      <address>
        <city>Kfar-Saba</city>
        <state>HaMerkaz</state>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972-97472262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 1702)</name>
      <address>
        <city>Petah Tikva</city>
        <state>HaMerkaz</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239378076</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center ( Site 1703)</name>
      <address>
        <city>Rehovot</city>
        <state>HaMerkaz</state>
        <zip>7661041</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Holy Family Hospital ( Site 1711)</name>
      <address>
        <city>Nazareth</city>
        <state>HaTsafon</state>
        <zip>1641101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>97246508981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 1705)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97248543018</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center. ( Site 1707)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5266202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235304961</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 1706)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abib</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236974907</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Centers LTD ( Site 1709)</name>
      <address>
        <city>Tel Aviv</city>
        <state>Tell Abīb</state>
        <zip>6971028</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>97237645177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center ( Site 1708)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235304961</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1700)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226777825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital ( Site 2601)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81527626111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 2613)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81471331111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center ( Site 2607)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81118119111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital ( Site 2600)</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81798456111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital ( Site 2616)</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81427788111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center ( Site 2606)</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81429844111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center ( Site 2612)</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81487221111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center Hospital and Research Institute ( Site 2611)</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81559895222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center ( Site 2605)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81432645431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital ( Site 2610)</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81245471111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital ( Site 2603)</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81822212291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital ( Site 2602)</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81963442111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital ( Site 2614)</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669421331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital ( Site 2608)</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335881111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR ( Site 2604)</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335200111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital ( Site 2615)</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81337848000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 2204)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82319201680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 2200)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+821090794697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 2201)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 2202)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 2203)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234101780</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tauranga Hospital ( Site 2302)</name>
      <address>
        <city>Tauranga</city>
        <state>Bay Of Plenty</state>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6475798000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canterbury Regional Cancer &amp; Blood Services ( Site 2303)</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Capital &amp; Coast District Health Board - Wellington Hospital ( Site 2301)</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6443855999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1800)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48501446778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki ( Site 1821)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48 530 770 073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Specjalistyczny im. dr Jozefa Psarskiego ( Site 1814)</name>
      <address>
        <city>Ostroleka</city>
        <state>Mazowieckie</state>
        <zip>07-410</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48600852881</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1899)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48502626262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Onkologiczny ( Site 1803)</name>
      <address>
        <city>Wieliszew</city>
        <state>Mazowieckie</state>
        <zip>05-135</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48227661500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 1819)</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48692267220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzkie Centrum Onkologii Copernicus ( Site 1817)</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48505993747</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Sp. z o.o. ( Site 1818)</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48501220811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1810)</name>
      <address>
        <city>Bielsko-Biala</city>
        <state>Slaskie</state>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48696414588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny nr 4 w Bytomiu ( Site 1807)</name>
      <address>
        <city>Bytom</city>
        <state>Slaskie</state>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1801)</name>
      <address>
        <city>Gliwice</city>
        <state>Slaskie</state>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48322788613</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dolnoslaskie Centrum Onkologii. ( Site 1820)</name>
      <address>
        <city>Wrocław</city>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48713689601</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHLN Hospital Santa Maria ( Site 2501)</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351217805097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacao Champalimaud ( Site 2500)</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351210480004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Santo Antonio ( Site 2503)</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351222077500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 2502)</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351225084008</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncological Dispensary ( Site 1901)</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Arkhangelskaya Oblast</state>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79212469153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1909)</name>
      <address>
        <city>Ufa</city>
        <state>Baskortostan, Respublika</state>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin NMRCO ( Site 1908)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031990675</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital with outpatient Clinic ( Site 1907)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79031691379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Rehabilitation Center ( Site 1912)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79264375889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Oncology Dispensary ( Site 1910)</name>
      <address>
        <city>Ryazan</city>
        <state>Ryazanskaya Oblast</state>
        <zip>390046</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79106436814</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Railway Hospital of OJSC ( Site 1913)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79052154918</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1900)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124399560</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1903)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79179315577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tomsk Scientific Research Institute of Oncology ( Site 1905)</name>
      <address>
        <city>Tomsk</city>
        <state>Tomskaya Oblast'</state>
        <zip>634028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79138223555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera - Chuac ( Site 1358)</name>
      <address>
        <city>A Coruna</city>
        <state>A Coruna [La Coruna]</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981178000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Oncologico Baselga.Hospital Quiron. ( Site 1352)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932381661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D Hebron ( Site 1357)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932746000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona ( Site 1353)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 1363)</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron de Madrid ( Site 1351)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521989</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia ( Site 1355)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961973583</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Arnau de Vilanova de Valencia ( Site 1369)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961976177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen ( Site 1364)</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34953220306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon ( Site 1367)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional ( Site 1370)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913875090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos ( Site 1354)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915495741</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre ( Site 1356)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913908626</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio ( Site 1360)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955015796</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital ( Site 2401)</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886912676024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 2400)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886623535354273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 2404)</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88622312345665080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center ( Site 2403)</name>
      <address>
        <city>Taipei</city>
        <zip>11259</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886228970011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital ( Site 2402)</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88633281200X3605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 2702)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675625054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2700)</name>
      <address>
        <city>Kryviy Rih</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675393937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Precarpathian Clinical Oncology Center ( Site 2707)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380502094000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal non profit enterprise Regional Clinical Oncology Center ( Site 2721)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380506556166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Khmelnitskiy Regional Onkology Dispensary ( Site 2704)</name>
      <address>
        <city>Khmelnitskiy</city>
        <state>Khmelnytska Oblast</state>
        <zip>29000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380505220030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI KhRC Kherson Regional Oncology Dispensary ( Site 2713)</name>
      <address>
        <city>Antonivka Village</city>
        <state>Kyivska Oblast</state>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509015487</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of the MoH of Ukraine ( Site 2719)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380503560549</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncology Centre ( Site 2716)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503818536</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Odesa Regional Clinical Hospital ( Site 2701)</name>
      <address>
        <city>Odesa</city>
        <state>Odeska Oblast</state>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380972147211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Odessa Regional Oncological Centre ( Site 2714)</name>
      <address>
        <city>Odesa</city>
        <state>Odeska Oblast</state>
        <zip>65055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380504261911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical center of the Limited Liability Company Yulis ( Site 2720)</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Zaporizka Oblast</state>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380667145005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust ( Site 1503)</name>
      <address>
        <city>Bristol</city>
        <state>Bristol, City Of</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441483571122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust ( Site 1500)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441483571122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital ( Site 1501)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442071887188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Georges University Hospital NHS Foundation Trust ( Site 1505)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442086721255</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust ( Site 1504)</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4407767311394</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colchester General Hospital ( Site 1508)</name>
      <address>
        <city>Colchester</city>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441206745084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham &amp; Solihull Heartlands Hospital NHS ( Site 1506)</name>
      <address>
        <city>Solihull</city>
        <zip>B91 2JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441214244060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital ( Site 1502)</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441872250000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

